ABRAXANE Side Effects

7014347-6 | Neuropathy Peripheral
on Sep 24, 2010 Female patient from UNITED STATES , 41 years of age, was diagnosed with breast cancer metastatic and was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: neuropathy peripheral. Abraxane dosage: 460mg Q3weeks Iv, Cycle 10 Of 12.

7010011-8 | Fluid Overload, Macular Oedema, Proteinuria, Renal Impairment, Visual Acuity Reduced
Patient was taking Abraxane (View Usage). Patient had the following side effects: fluid overload, macular oedema, proteinuria, renal impairment, visual acuity reduced on Sep 02, 2010 from UNITED STATES Additional patient health information: Female patient , 65 years of age, was diagnosed with breast cancer metastatic and. Abraxane dosage: . During the same period patient was treated with BEVACIZUMAB (BEVACIZUMAB) (View Bevacizumab (bevacizumab) Review and Bevacizumab (bevacizumab) Label ).

7010005-2 | Cataract Operation, Lacrimation Increased, Macular Oedema, Visual Impairment
Adverse event was reported on Sep 02, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: ) was diagnosed with breast cancer metastatic and. Location: UNITED STATES , 58 years of age, After Abraxane was administered, patient had the following side effects: cataract operation, lacrimation increased, macular oedema, visual impairment. During the same period patient was treated with BEVACIZUMAB (BEVACIZUMAB) (View Bevacizumab (bevacizumab) Review and Bevacizumab (bevacizumab) Label ).

6982339-9 | Convulsion, Dizziness, Haemoglobin Decreased, Infection, Moaning, Purulence, Rhinorrhoea, Staring, Unresponsive To Stimuli
on Aug 30, 2010 Male patient from UNITED STATES , 49 years of age, was diagnosed with malignant melanoma and was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion, dizziness (What is dizziness?), haemoglobin decreased, infection (What is infection?), moaning, purulence, rhinorrhoea, staring, unresponsive to stimuli. Abraxane dosage: . During the same period patient was treated with BEVACIZUMAB (BEVACIZUMAB) (View Bevacizumab (bevacizumab) Review and Bevacizumab (bevacizumab) Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ). Patient was hospitalized.


6971861-7 | Chills, Orthostatic Hypotension, Pyrexia
on Sep 08, 2010 Female patient from UNITED STATES , weighting 110.0 lb, was diagnosed with pancreatic carcinoma and was treated with Abraxane (View Usage). Patient had the following side effects: chills, orthostatic hypotension, pyrexia. Abraxane dosage: 147 Mg D1, D8, D15/cycle Iv. During the same period patient was treated with VANDETANIB (300 Mg Qd X 28 Days Po) (View Vandetanib Review and Vandetanib Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), VICODIN (View Vicodin Review and Vicodin Label ), COLACE (View Colace Review and Colace Label ), MIRALAX (View Miralax Review and Miralax Label ), COMPAZINE (View Compazine Review and Compazine Label ), FLOMAX (View Flomax Review and Flomax Label ). Patient was hospitalized.

6945515-7 | Dehydration, Diarrhoea, Haematocrit Decreased, Haemoglobin Decreased, Hypophagia, Neutropenia, Pulmonary Embolism, Renal Failure, Respiratory Distress
Patient was taking Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: dehydration, diarrhoea, haematocrit decreased, haemoglobin decreased, hypophagia, neutropenia, pulmonary embolism (What is pulmonary embolism?), renal failure, respiratory distress on Aug 17, 2010 from UNITED STATES Additional patient health information: Male patient , 64 years of age, weighting 142.0 lb, was diagnosed with non-small cell lung cancer and. Abraxane dosage: 570 Mg. During the same period patient was treated with CARBOPLATIN (440 Mg) (View Carboplatin Review and Carboplatin Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), BENZONATATE (View Benzonatate Review and Benzonatate Label ), CALCIUM CITRATE (CALCIUM CITRATE) (View Calcium Citrate (calcium Citrate) Review and Calcium Citrate (calcium Citrate) Label ), CELEBREX (View Celebrex Review and Celebrex Label ), CENTRUM ONE (CENTRUM) (View Centrum One (centrum) Review and Centrum One (centrum) Label ), MULTIVITAMIN (MUTLIVITAMINS) (View Multivitamin (mutlivitamins) Review and Multivitamin (mutlivitamins) Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ). Patient was hospitalized.

6945514-5 | Abdominal Pain, Asthenia, Body Temperature Increased, Brain Mass, Central Nervous System Lesion, Feeling Cold, Meningioma, Metastases To Central Nervous System, Nausea
Adverse event was reported on Aug 16, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: 100 Mg) was diagnosed with pancreatic carcinoma and. Location: UNITED STATES , 66 years of age, weighting 149.9 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), asthenia, body temperature increased, brain mass, central nervous system lesion, feeling cold, meningioma, metastases to central nervous system, nausea (What is nausea?). During the same period patient was treated with ERLOTINIB HYDROCHLORIDE (100 Mg, Oral) (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), GEMCITABINE (1000 Mg, Intravenous) (View Gemcitabine Review and Gemcitabine Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), LOVASTATIN (View Lovastatin Review and Lovastatin Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MIRALAX (View Miralax Review and Miralax Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ). Patient was hospitalized.

6945494-2 | Dehydration, Dyspnoea, Renal Failure Acute
on Aug 16, 2010 Female patient from UNITED STATES , 63 years of age, was diagnosed with breast cancer metastatic and was treated with Abraxane (View Usage). Patient had the following side effects: dehydration, dyspnoea, renal failure acute. Abraxane dosage: 100 Mg/m2. During the same period patient was treated with LAPATINIB (1000 Mg, Oral) (View Lapatinib Review and Lapatinib Label ). Patient was hospitalized.

6942315-9 | Blood Ph Decreased, Blood Sodium Decreased, Dehydration, Diarrhoea, Haematocrit Decreased, Haemoglobin Decreased, Hypophagia, Neutropenia, Pulmonary Embolism
on Aug 10, 2010 Male patient from UNITED STATES , 64 years of age, weighting 142.0 lb, was diagnosed with non-small cell lung cancer and was treated with Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: blood ph decreased, blood sodium decreased, dehydration, diarrhoea, haematocrit decreased, haemoglobin decreased, hypophagia, neutropenia, pulmonary embolism (What is pulmonary embolism?). Abraxane dosage: 570 Mg. During the same period patient was treated with CARBOPLATIN (440 Mg) (View Carboplatin Review and Carboplatin Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), BENZONATATE (View Benzonatate Review and Benzonatate Label ), CALCIUM CITRATE (CALCIUM CITRATE) (View Calcium Citrate (calcium Citrate) Review and Calcium Citrate (calcium Citrate) Label ), CELEBREX (View Celebrex Review and Celebrex Label ), CENTRUM ONE (CENRUM) (View Centrum One (cenrum) Review and Centrum One (cenrum) Label ), MULTIVITAMIN (View Multivitamin Review and Multivitamin Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ). Patient was hospitalized.

6939519-8 | Blood Pressure Diastolic Decreased, Blood Pressure Systolic Increased, Duodenal Ulcer Haemorrhage, Erosive Duodenitis, Haematocrit Decreased, Haemoglobin Decreased, Neutrophil Count Decreased, Platelet Count Decreased, Prothrombin Time Shortened
Patient was taking Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure diastolic decreased, blood pressure systolic increased, duodenal ulcer haemorrhage, erosive duodenitis, haematocrit decreased, haemoglobin decreased, neutrophil count decreased, platelet count decreased, prothrombin time shortened on Aug 13, 2010 from UKRAINE Additional patient health information: Male patient , 77 years of age, weighting 166.4 lb, was diagnosed with transitional cell carcinoma and. Abraxane dosage: 494 Mg. During the same period patient was treated with CARBOPLATIN (365 Mg) (View Carboplatin Review and Carboplatin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), CALCIUM VITAMIN D (CALCIUM WITH VITAMIN D) (View Calcium Vitamin D (calcium With Vitamin D) Review and Calcium Vitamin D (calcium With Vitamin D) Label ), GLUCOSAMINE COMPLEX (GLUCOSAMINE) (View Glucosamine Complex (glucosamine) Review and Glucosamine Complex (glucosamine) Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), COMPAZINE (View Compazine Review and Compazine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6925068-X | Ascites, Cardiac Failure Congestive, Oedema
Adverse event was reported on Aug 02, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: Received For 9 Months Total, Intravenous) was diagnosed with breast cancer metastatic and. Location: UNITED STATES , 65 years of age, Patient had the following side effects: ascites, cardiac failure congestive, oedema. During the same period patient was treated with AVASTIN (View Avastin Review and Avastin Label ). Patient was hospitalized.

6918139-5 | Abdominal Pain, Body Temperature Increased, Brain Mass, Central Nervous System Lesion, Feeling Cold, Meningioma, Metastasis, Nausea
on Jul 29, 2010 Female patient from UNITED STATES , 66 years of age, weighting 149.9 lb, was diagnosed with pancreatic carcinoma and was treated with Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), body temperature increased, brain mass, central nervous system lesion, feeling cold, meningioma, metastasis, nausea (What is nausea?). Abraxane dosage: 100 Mg. During the same period patient was treated with ERLOTINIB HYDROCHLORIDE (100 Mg, Oral) (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), GEMCITABINE (1000 Mg, Intravenous) (View Gemcitabine Review and Gemcitabine Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), LOVASTATIN (View Lovastatin Review and Lovastatin Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MIRALAX (View Miralax Review and Miralax Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ). Patient was hospitalized.

6918138-3 | Haemarthrosis, Haemoglobin Decreased, Hyponatraemia, Hypotension, Joint Effusion, Neutrophil Count Decreased, Platelet Count Decreased, Red Blood Cell Sedimentation Rate Increased, White Blood Cell Count Decreased
on Jul 30, 2010 Male patient from UNITED STATES , 79 years of age, weighting 185.4 lb, was diagnosed with transitional cell carcinoma and was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: haemarthrosis, haemoglobin decreased, hyponatraemia, hypotension, joint effusion, neutrophil count decreased, platelet count decreased, red blood cell sedimentation rate increased, white blood cell count decreased. Abraxane dosage: 533 Mg. During the same period patient was treated with GEMCITABINE (1640 Mg) (View Gemcitabine Review and Gemcitabine Label ), CARBOPLATIN (492 Mg) (View Carboplatin Review and Carboplatin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), COLACE (DOCUSATE SODIUM) (View Colace (docusate Sodium) Review and Colace (docusate Sodium) Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), PROCHLOPERAZINE MALEATE (PROCHLORPERAZINE MALEATE) (View Prochloperazine Maleate (prochlorperazine Maleate) Review and Prochloperazine Maleate (prochlorperazine Maleate) Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), SATALOL (View Satalol Review and Satalol Label ).

6918137-1 | Apparent Life Threatening Event, Dehydration, Dyspnoea, Renal Failure Acute
Patient was taking Abraxane (View Usage). Patient had the following side effects: apparent life threatening event, dehydration, dyspnoea, renal failure acute on Jul 28, 2010 from UNITED STATES Additional patient health information: Female patient , 63 years of age, was diagnosed with breast cancer metastatic and. Abraxane dosage: 100 Mg/m2. During the same period patient was treated with LAPATINIB (1000 Mg, Oral) (View Lapatinib Review and Lapatinib Label ). Patient was hospitalized.

6916663-2 | Beta Haemolytic Streptococcal Infection, Blood Culture Positive, Cellulitis, Lymphatic Obstruction, Oedema
Adverse event was reported on Aug 09, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: Abraxane Every 8 Weeks Iv) was diagnosed with breast cancer metastatic and. Location: UNITED STATES , weighting 129.9 lb, After Abraxane was administered, patient had the following side effects: beta haemolytic streptococcal infection, blood culture positive, cellulitis (What is cellulitis?), lymphatic obstruction, oedema. During the same period patient was treated with AVASTIN (Avastin Every 14 Days Iv) (View Avastin Review and Avastin Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), ZOSYN (View Zosyn Review and Zosyn Label ), KEFZOL (View Kefzol Review and Kefzol Label ). Patient was hospitalized.

6905553-7 | Abdominal Pain, Colitis, Diarrhoea, Nausea
on Jul 26, 2010 Female patient from UNITED STATES , 49 years of age, weighting 200.6 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), colitis, diarrhoea, nausea (What is nausea?). Abraxane dosage: . During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), SOMA (View Soma Review and Soma Label ), ACIPHEX (View Aciphex Review and Aciphex Label ), LORTAB (VICODIN) (View Lortab (vicodin) Review and Lortab (vicodin) Label ). Patient was hospitalized.

6903561-3 | Dehydration, Diarrhoea, Hypotension, Neutrophil Count Decreased, Peripheral Sensory Neuropathy, Sepsis, Stomatitis, Urinary Tract Infection
on Jul 22, 2010 Female patient from UNITED STATES , 61 years of age, weighting 112.0 lb, was diagnosed with pancreatic carcinoma and was treated with Abraxane (View Usage). Patient had the following side effects: dehydration, diarrhoea, hypotension, neutrophil count decreased, peripheral sensory neuropathy, sepsis (What is sepsis?), stomatitis, urinary tract infection (What is urinary tract infection?). Abraxane dosage: 184 Mg Days 1, 8 And 15 (184 Mg), Intravenous. During the same period patient was treated with ERLOTINIB HYDROCHLORIDE ((100 Mg), Oral) (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), GEMCITABINE (1102 Mg Days 1, 8, And 15 (1102 Mg), Intravenous) (View Gemcitabine Review and Gemcitabine Label ), IMODIUM (View Imodium Review and Imodium Label ), NADOLOL (View Nadolol Review and Nadolol Label ), DOXYCYCLINE (View Doxycycline Review and Doxycycline Label ), WESTCORT (HYDROCORTISONE VALERATE) (View Westcort (hydrocortisone Valerate) Review and Westcort (hydrocortisone Valerate) Label ). Patient was hospitalized.

6903557-1 | Abdominal Pain, Asthenia, Feeling Cold, Meningioma, Nausea, Night Sweats, Pyrexia, Temporal Arteritis
Patient was taking Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), asthenia, feeling cold, meningioma, nausea (What is nausea?), night sweats, pyrexia, temporal arteritis on Jul 22, 2010 from UNITED STATES Additional patient health information: Female patient , 66 years of age, weighting 149.9 lb, was diagnosed with pancreatic carcinoma and. Abraxane dosage: (100 Mg). During the same period patient was treated with ERLOTINIB HYDROCHLORIDE ((100 Mg), Oral) (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), GEMCITABINE ((1000 Mg), Intravenous) (View Gemcitabine Review and Gemcitabine Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), LOVASTATIN (View Lovastatin Review and Lovastatin Label ), DICLOFENAC SODIUM (View Diclofenac Sodium Review and Diclofenac Sodium Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), MIRALAX (View Miralax Review and Miralax Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ). Patient was hospitalized.

6901449-5 | Interstitial Lung Disease
Adverse event was reported on Jul 22, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: (240 Mg)) was diagnosed with pancreatic carcinoma and. Location: UNITED STATES , 69 years of age, weighting 187.0 lb, Patient experienced the following unwanted or unexpected effects: interstitial lung disease. During the same period patient was treated with ERLOTINIB HYDROCHLORIDE ((100 Mg), Oral) (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), GEMCITABINE ((1920 Mg), Intravenous) (View Gemcitabine Review and Gemcitabine Label ), PREMARIN (View Premarin Review and Premarin Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), PROZAC (View Prozac Review and Prozac Label ), LIPITOR (View Lipitor Review and Lipitor Label ), PREVACID (View Prevacid Review and Prevacid Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6856825-6 | Blood Pressure Diastolic Decreased, Breath Sounds Abnormal, Cardiac Murmur, Faeces Discoloured, Gastrointestinal Haemorrhage, Haemoglobin Decreased, Neutrophil Count Decreased, Platelet Count Decreased, Rash Erythematous
on Jul 08, 2010 Male patient from UNITED STATES , 77 years of age, weighting 151.9 lb, was diagnosed with transitional cell carcinoma and was treated with Abraxane (View Usage). Patient had the following side effects: blood pressure diastolic decreased, breath sounds abnormal, cardiac murmur, faeces discoloured, gastrointestinal haemorrhage, haemoglobin decreased, neutrophil count decreased, platelet count decreased, rash erythematous. Abraxane dosage: (494 Mg). During the same period patient was treated with GEMCITABINE ((1520 Mg)) (View Gemcitabine Review and Gemcitabine Label ), CARBOPLATIN ((365 Mg)) (View Carboplatin Review and Carboplatin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CALCIUM VITAMIN D3 (CALCIUM D3 'STADA^) (View Calcium Vitamin D3 (calcium D3 'stada^) Review and Calcium Vitamin D3 (calcium D3 'stada^) Label ), EMLA CREAM (EMLA) (View Emla Cream (emla) Review and Emla Cream (emla) Label ), COMPAZINE (View Compazine Review and Compazine Label ). Patient was hospitalized.

6843059-4 | Activated Partial Thromboplastin Time Shortened, Asthenia, Conjunctival Pallor, Diverticulum Intestinal Haemorrhagic, Dizziness, Gastrointestinal Haemorrhage, Haematocrit Decreased, Haemoglobin Decreased, Haemorrhoidal Haemorrhage
on Jul 06, 2010 Female patient from UNITED STATES , 57 years of age, weighting 1459 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: activated partial thromboplastin time shortened, asthenia, conjunctival pallor, diverticulum intestinal haemorrhagic, dizziness (What is dizziness?), gastrointestinal haemorrhage, haematocrit decreased, haemoglobin decreased, haemorrhoidal haemorrhage. Abraxane dosage: (174 Mg). During the same period patient was treated with AVASTIN ((1004 Mg)) (View Avastin Review and Avastin Label ), CARBOPLATIN ((715 Mg)) (View Carboplatin Review and Carboplatin Label ), B STRESS COMPLEX (BECOSYM FORTE) (View B Stress Complex (becosym Forte) Review and B Stress Complex (becosym Forte) Label ), COMPAZINE (View Compazine Review and Compazine Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6840071-6 | Diarrhoea, Vomiting
Patient was taking Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, vomiting on Jul 13, 2010 from UNITED STATES Additional patient health information: Female patient , 81 years of age, weighting 85.00 lb, was diagnosed with small cell lung cancer extensive stage and. Abraxane dosage: 319 Mg, Q 3weeks, Iv. During the same period patient was treated with CARBOPLATIN (Aug 6, Q 3wks, Iv) (View Carboplatin Review and Carboplatin Label ), PLAVIX (View Plavix Review and Plavix Label ), MEGACE (View Megace Review and Megace Label ). Patient was hospitalized.

6838899-1 | Back Pain, Dyspnoea, Erythema
Adverse event was reported on Jun 30, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: (298 Mg), Intravenous) was diagnosed with breast cancer (What is breast cancer?) and. Location: UNITED KINGDOM , 51 years of age, weighting 138.2 lb, Patient had the following side effects: back pain (What is back pain?), dyspnoea, erythema. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

6835369-1 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Febrile Neutropenia
on Jun 28, 2010 Female patient from UNITED STATES , 39 years of age, weighting 137.9 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, febrile neutropenia. Abraxane dosage: (135 Mg). During the same period patient was treated with SUNITINIB MALATE ((25 Mg), Oral) (View Sunitinib Malate Review and Sunitinib Malate Label ), TRIAMCINOLONE ACETONIDE (View Triamcinolone Acetonide Review and Triamcinolone Acetonide Label ), ZYRTEC (View Zyrtec Review and Zyrtec Label ), BENADRYL (View Benadryl Review and Benadryl Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), XANAX (View Xanax Review and Xanax Label ), ZOFRAN (View Zofran Review and Zofran Label ). Patient was hospitalized.

6831060-6 | Arthralgia, Haemoglobin Decreased, Musculoskeletal Pain, Nausea, Pneumothorax, Tachycardia, White Blood Cell Count Decreased
on Jun 29, 2010 Female patient from UNITED STATES , 22 years of age, weighting 454.2 lb, was diagnosed with neoplasm malignant and was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: arthralgia, haemoglobin decreased, musculoskeletal pain, nausea (What is nausea?), pneumothorax, tachycardia, white blood cell count decreased. Abraxane dosage: . During the same period patient was treated with VIDAZA (View Vidaza Review and Vidaza Label ), DILAUDID (View Dilaudid Review and Dilaudid Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), GRANISETRON (GRANISETRON) (View Granisetron (granisetron) Review and Granisetron (granisetron) Label ). Patient was hospitalized.

6821984-8 | Asthenia, Decreased Appetite, Dehydration, Dizziness, Hyperhidrosis, Hypophagia, Nausea, Presyncope
Patient was taking Abraxane (View Usage). Patient had the following side effects: asthenia, decreased appetite, dehydration, dizziness (What is dizziness?), hyperhidrosis, hypophagia, nausea (What is nausea?), presyncope on Jul 07, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 176.8 lb, was diagnosed with dehydration and. Abraxane dosage: . During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ). Patient was hospitalized.

6821983-6 | Gastrointestinal Haemorrhage
Adverse event was reported on Jul 07, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: ) was diagnosed with gastrointestinal haemorrhage and. Location: UNITED STATES , weighting 145.9 lb, After Abraxane was administered, patient had the following side effects: gastrointestinal haemorrhage. During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), AVASTIN (View Avastin Review and Avastin Label ). Patient was hospitalized.

6819863-5 | Herpes Zoster Disseminated
on Jun 23, 2010 Female patient from UNITED STATES , 69 years of age, weighting 135.8 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: herpes zoster disseminated. Abraxane dosage: (164 Mf), Intravenous. During the same period patient was treated with CARBOPLATIN ((197 Mg), Intravenous) (View Carboplatin Review and Carboplatin Label ). Patient was hospitalized.

6819862-3 | Pneumonia Aspiration, Pulmonary Embolism
on Jun 24, 2010 Male patient from UNITED STATES , 52 years of age, weighting 160.0 lb, was diagnosed with head and neck cancer (What is head and neck cancer?) and was treated with Abraxane (View Usage). Patient had the following side effects: pneumonia aspiration, pulmonary embolism (What is pulmonary embolism?). Abraxane dosage: (150 Mg/m2), Intravenous. During the same period patient was treated with CARBOPLATIN ((1.5 Auc)) (View Carboplatin Review and Carboplatin Label ), ATIVAN (View Ativan Review and Ativan Label ), ATROVENT (View Atrovent Review and Atrovent Label ), COMPAZINE (View Compazine Review and Compazine Label ), DECADRON (View Decadron Review and Decadron Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), FLOVENT (View Flovent Review and Flovent Label ). Patient was hospitalized.

6810749-9 | Asthenia, Dyspnoea, Haemoglobin Decreased, Haemorrhoidal Haemorrhage
Patient was taking Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: asthenia, dyspnoea, haemoglobin decreased, haemorrhoidal haemorrhage on Jun 29, 2010 from UNITED STATES Additional patient health information: Female patient , 57 years of age, weighting 197.8 lb, was diagnosed with breast cancer metastatic and. Abraxane dosage: 194mg -100mg/m2- Weekly 3 /4 Weeks Iv. During the same period patient was treated with CARBOPLATIN NA NA (256 Mg -auc 2- Weekly 3/4 Weeks Iv) (View Carboplatin Na Na Review and Carboplatin Na Na Label ), XANAX (View Xanax Review and Xanax Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), CYMBALTA (View Cymbalta Review and Cymbalta Label ), PROZAC (View Prozac Review and Prozac Label ), LIPITOR (View Lipitor Review and Lipitor Label ), NORVASC (View Norvasc Review and Norvasc Label ). Patient was hospitalized.

6809618-X | Escherichia Sepsis, Gingival Bleeding, Pain, Platelet Count Decreased
Adverse event was reported on Jan 31, 2009 by a Female patient taking Abraxane (View Usage) (Dosage: (260 Mg/m2)) was diagnosed with breast cancer (What is breast cancer?) and. Location: UNITED ARAB EMIRATES , 44 years of age, Patient experienced the following unwanted or unexpected effects: escherichia sepsis, gingival bleeding, pain (What is pain?), platelet count decreased.

6809448-9 | Pruritus, Urticaria
on Sep 03, 2009 Female patient from UNITED ARAB EMIRATES , 58 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Abraxane (View Usage). Patient had the following side effects: pruritus, urticaria. Abraxane dosage: 260 Mg/m2.

6798121-1 | Anaphylactic Shock, Hypertension
on Jun 11, 2010 Male patient from INDIA , 36 years of age, weighting 114.6 lb, was diagnosed with pancreatic carcinoma and was treated with Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: anaphylactic shock, hypertension. Abraxane dosage: 200 Mg, One Dose Given. During the same period patient was treated with GEMCITABINE (1 Gm) (View Gemcitabine Review and Gemcitabine Label ).

6773632-3 | Dyspnoea, Feeling Abnormal, Flushing
Patient was taking Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: dyspnoea, feeling abnormal, flushing on Jun 08, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 70 years of age, weighting 147.0 lb, was diagnosed with breast cancer (What is breast cancer?) and. Abraxane dosage: (140 Mg), Intravenous. During the same period patient was treated with CHLORHEXIDINE GLUCONATE (View Chlorhexidine Gluconate Review and Chlorhexidine Gluconate Label ), METOCLOPRAMIDE (METOCLOPRAMIDE) (View Metoclopramide (metoclopramide) Review and Metoclopramide (metoclopramide) Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ), ZOLEDRONIC ACID (View Zoledronic Acid Review and Zoledronic Acid Label ).

6773631-1 | Dizziness, Dyspnoea, Flushing, Oxygen Saturation Decreased
Adverse event was reported on Jun 08, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: (136 Mg), Intravenous) was diagnosed with breast cancer (What is breast cancer?) and. Location: UNITED KINGDOM , 44 years of age, weighting 147.0 lb, Patient had the following side effects: dizziness (What is dizziness?), dyspnoea, flushing, oxygen saturation decreased. During the same period patient was treated with CETIRIZINE HCL (View Cetirizine Hcl Review and Cetirizine Hcl Label ), CHLORHEXIDINE GLUCONATE (View Chlorhexidine Gluconate Review and Chlorhexidine Gluconate Label ), CODEINE LINCTUS) (View Codeine Linctus) Review and Codeine Linctus) Label ), METOCLOPRAMIDE (METOCLOPRAMIDE) (View Metoclopramide (metoclopramide) Review and Metoclopramide (metoclopramide) Label ).

6768183-6 | Leukocytoclastic Vasculitis
on May 26, 2010 Female patient from GERMANY , 48 years of age, was diagnosed with neoplasm malignant and was treated with Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: leukocytoclastic vasculitis. Abraxane dosage: (150 Mg). Patient was hospitalized.

6767939-3 | Aortic Dissection Rupture
on May 25, 2010 Female patient from UNITED KINGDOM , 75 years of age, weighting 110.2 lb, was diagnosed with uterine cancer (What is uterine cancer?) and was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: aortic dissection rupture. Abraxane dosage: .

6767928-9 | Alanine Aminotransferase Increased, Blood Bilirubin Increased
Patient was taking Abraxane (View Usage). Patient had the following side effects: alanine aminotransferase increased, blood bilirubin increased on May 27, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 70 years of age, . Abraxane dosage: . During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), GABAPENTIN (View Gabapentin Review and Gabapentin Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ). Patient was hospitalized.

6767925-3 | Bacterial Sepsis, Lactic Acidosis, Mucosal Inflammation, Multi-organ Failure, Pancytopenia, Rhabdomyolysis, Tumour Lysis Syndrome
Adverse event was reported on May 27, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: (260 Mg/m2)) was diagnosed with breast cancer metastatic and. Location: AUSTRALIA , 64 years of age, After Abraxane was administered, patient had the following side effects: bacterial sepsis, lactic acidosis, mucosal inflammation, multi-organ failure, pancytopenia, rhabdomyolysis, tumour lysis syndrome. During the same period patient was treated with INSULIN (INSULIN) (View Insulin (insulin) Review and Insulin (insulin) Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), STATIN (View Statin Review and Statin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ).

6767256-1 | Cardio-respiratory Arrest, Collapse Of Lung, Pleural Effusion
on Jun 11, 2010 Male patient from UNITED STATES , weighting 158.7 lb, was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest, collapse of lung, pleural effusion. Abraxane dosage: . During the same period patient was treated with VANDETANIB (View Vandetanib Review and Vandetanib Label ), METFORMIN (View Metformin Review and Metformin Label ), CREON (View Creon Review and Creon Label ), BENEFIBER (View Benefiber Review and Benefiber Label ), IMODIUM (View Imodium Review and Imodium Label ), VICODIN (View Vicodin Review and Vicodin Label ), PROZAC (View Prozac Review and Prozac Label ).

6762929-9 | Neutropenia, Syncope, White Blood Cell Count Decreased
on Jun 08, 2010 Female patient from UNITED STATES , 81 years of age, weighting 86.00 lb, was diagnosed with small cell lung cancer extensive stage and was treated with Abraxane (View Usage). Patient had the following side effects: neutropenia, syncope, white blood cell count decreased. Abraxane dosage: 319 Mg, Q 3 Weeks, Iv. During the same period patient was treated with CARBOPLATIN (Auc 6, Q 3 Weeks, Iv) (View Carboplatin Review and Carboplatin Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), PLAVIX (View Plavix Review and Plavix Label ), BYSTOLIC (View Bystolic Review and Bystolic Label ). Patient was hospitalized.

6762925-1 | Syncope
Patient was taking Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: syncope on Jun 08, 2010 from UNITED STATES Additional patient health information: Female patient , 81 years of age, weighting 86.00 lb, was diagnosed with small cell lung cancer extensive stage and. Abraxane dosage: 319 Mg, Q 3 Weeks, Iv. During the same period patient was treated with CARBOPLATIN (Auc 6 Q3 Weeks Iv) (View Carboplatin Review and Carboplatin Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), PLAVIX (View Plavix Review and Plavix Label ), BYSTOLIC (View Bystolic Review and Bystolic Label ). Patient was hospitalized.

6759444-5 | Inappropriate Antidiuretic Hormone Secretion
Adverse event was reported on May 21, 2010 by a Male patient taking Abraxane (View Usage) (Dosage: (504 Mg)) was diagnosed with transitional cell carcinoma and. Location: UNITED STATES , 72 years of age, Patient experienced the following unwanted or unexpected effects: inappropriate antidiuretic hormone secretion. During the same period patient was treated with CARBOPLATIN ((450 Mg)) (View Carboplatin Review and Carboplatin Label ), GEMCITABINE ((1552 Mg)) (View Gemcitabine Review and Gemcitabine Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CALCIUM CARBONATE (View Calcium Carbonate Review and Calcium Carbonate Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), OLMESARTAN (OLMESARTAN MEDOXOMIL) (View Olmesartan (olmesartan Medoxomil) Review and Olmesartan (olmesartan Medoxomil) Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

6759443-3 | Blood Sodium Decreased, Cellulitis Staphylococcal, Cellulitis Streptococcal, Haematocrit Decreased, Haemoglobin Decreased, Herpes Simplex, Herpes Zoster, Neutropenia, Platelet Count Decreased
on May 19, 2010 Female patient from UNITED STATES , 60 years of age, was diagnosed with metastatic malignant melanoma and was treated with Abraxane (View Usage). Patient had the following side effects: blood sodium decreased, cellulitis staphylococcal, cellulitis streptococcal, haematocrit decreased, haemoglobin decreased, herpes simplex (What is herpes simplex?), herpes zoster, neutropenia, platelet count decreased. Abraxane dosage: (200 Mg/m2, Every 21 Days), Intravenous. During the same period patient was treated with CARBOPLATIN ((auc 6 Every 21 Days), Intravenous) (View Carboplatin Review and Carboplatin Label ), MP 470 HYDROCHLORIDE ((800 Mg), Oral) (View Mp 470 Hydrochloride Review and Mp 470 Hydrochloride Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), ESTRADIOL (View Estradiol Review and Estradiol Label ), ALPHA LIPOIC ACID (THIOCTIC ACID) (View Alpha Lipoic Acid (thioctic Acid) Review and Alpha Lipoic Acid (thioctic Acid) Label ). Patient was hospitalized.

6750548-X | Condition Aggravated, Pleural Effusion
on May 28, 2010 Male patient from UNITED STATES , weighting 158.7 lb, was diagnosed with pancreatic carcinoma and was treated with Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: condition aggravated, pleural effusion. Abraxane dosage: 188 Mg D1, D8 D15/cycle 042. During the same period patient was treated with VANDETANIB (300 Mg Qd X 6 Days 047) (View Vandetanib Review and Vandetanib Label ), METFORMIN (View Metformin Review and Metformin Label ), CREON (View Creon Review and Creon Label ), BENEFIBER (View Benefiber Review and Benefiber Label ), IMODIUM (View Imodium Review and Imodium Label ), VICODIN (View Vicodin Review and Vicodin Label ), PROZAC (View Prozac Review and Prozac Label ). Patient was hospitalized.

6750404-7 | Dehydration, Gastroenteritis
Patient was taking Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: dehydration, gastroenteritis (What is gastroenteritis?) on May 14, 2010 from UNITED STATES Additional patient health information: Female patient , 49 years of age, weighting 200.6 lb, was diagnosed with breast cancer (What is breast cancer?) and. Abraxane dosage: . During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), CYTOXAN (View Cytoxan Review and Cytoxan Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), SOMA (View Soma Review and Soma Label ), ACIPHEX (View Aciphex Review and Aciphex Label ), LORTAB (VICODIN) (View Lortab (vicodin) Review and Lortab (vicodin) Label ). Patient was hospitalized.

6749710-1 | Confusional State, Lactic Acidosis, Mucosal Inflammation, Multi-organ Failure, Pancytopenia, Rhabdomyolysis, Sepsis, Tumour Lysis Syndrome, Vomiting
Adverse event was reported on May 14, 2010 by a Female patient taking Abraxane (View Usage) (Dosage: (260 Mg/m2)) was diagnosed with breast cancer metastatic and. Location: AUSTRALIA , 64 years of age, Patient had the following side effects: confusional state, lactic acidosis, mucosal inflammation, multi-organ failure, pancytopenia, rhabdomyolysis, sepsis (What is sepsis?), tumour lysis syndrome, vomiting. During the same period patient was treated with INSULIN (INSULIN) (View Insulin (insulin) Review and Insulin (insulin) Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), STATIN (View Statin Review and Statin Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ).

6719670-8 | Lymphopenia, Neutropenia
on May 10, 2010 Male patient from UNITED STATES , weighting 125.7 lb, was diagnosed with squamous cell carcinoma and was treated with Abraxane (View Usage). After Abraxane was administered, patient had the following side effects: lymphopenia, neutropenia. Abraxane dosage: 25 Mg/m2 Weekly Iv. During the same period patient was treated with ZOFRAN (View Zofran Review and Zofran Label ), DECADRON (View Decadron Review and Decadron Label ), COMPAZINE (View Compazine Review and Compazine Label ).

6700243-8 | Dry Eye, Hypoaesthesia Eye, Optic Neuropathy
on Apr 12, 2010 Female patient from UNITED KINGDOM , 52 years of age, was diagnosed with breast cancer (What is breast cancer?) and was treated with Abraxane (View Usage). Patient experienced the following unwanted or unexpected effects: dry eye, hypoaesthesia eye, optic neuropathy. Abraxane dosage: . During the same period patient was treated with LEFLUNOMIDE (View Leflunomide Review and Leflunomide Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), ROSIGLITAZONE (View Rosiglitazone Review and Rosiglitazone Label ), TRASTUZUMAB (TRASTUZUMAB) (View Trastuzumab (trastuzumab) Review and Trastuzumab (trastuzumab) Label ).

6698512-3 | Asthenia, Disease Progression
Patient was taking Abraxane (View Usage). Patient had the following side effects: asthenia, disease progression on Apr 26, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 199.5 lb, was diagnosed with pancreatic carcinoma and. Abraxane dosage: 200 Mg D1,d8,d15/cycle 042. During the same period patient was treated with VANDETANIB (300 Mg Qd X 28 Days 047) (View Vandetanib Review and Vandetanib Label ), LOVENOX (View Lovenox Review and Lovenox Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), OXYCONTIN (View Oxycontin Review and Oxycontin Label ), SPIRONOLACTONE (View Spironolactone Review and Spironolactone Label ), ZOLPIDEM (View Zolpidem Review and Zolpidem Label ).